PATENT CLAIM ANALYSIS

Application Number: 16025009
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2018-10
Patent Classification: ["424", "449000"]

Abstract:
The disclosure generally relates to tamper-resistant transdermal dosage forms. The dosage forms can comprise an active agent and more than one antagonist reservoir.

Claim (Index 18):
The transdermal system of  claim 14 , wherein the ratio of the naltrexone, or a pharmaceutically acceptable salt thereof, to the fentanyl, or a pharmaceutically acceptable salt thereof, extracted from the dosage form at room temperature is at least 6.0:1 after 30 minutes of tampering.

Metadata:
- Claim Count in Document: 4.0
- Percentile: 95.0
- Lexical Diversity: 1.19048
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14757954', '10835535', '11281884', '14863688', '10420428']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7823048568624252
- 35 USC 102 Novelty (BERT): 0.5497155699895727
- Combined Prediction Score: 0.75904592817514
- Mean Citation Score: 319.34892
- Max Citation Score: 400.73453
- Similarity Product: 275.363395305171

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test